Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Ultragenyx Pharmaceutical Inc., Arrowhead Pharmaceuticals or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Ultragenyx Pharmaceutical Inc., Arrowhead Pharmaceuticals and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Ultragenyx Pharmaceutical Inc., Arrowhead Pharmaceuticals and Inc.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company’s products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701, an adeno-associated AAV9 gene therapy which is in Phase 2 clinical trial for the treatment of Wilson liver disease. The company has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Regeneron; and Abeona. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.

Latest Biotechnology and Ultragenyx Pharmaceutical Inc., Arrowhead Pharmaceuticals, Inc. Stock News

As of September 10, 2026, Ultragenyx Pharmaceutical Inc. had a $1.4 billion market capitalization, compared to the Biotechnology median of $272.7 million. Ultragenyx Pharmaceutical Inc.’s stock is down 37.7% in 2026, down 3.4% in the previous five trading days and down 54.29% in the past year.

Currently, Ultragenyx Pharmaceutical Inc. does not have a price-earnings ratio. Ultragenyx Pharmaceutical Inc.’s trailing 12-month revenue is $717.0 million with a -81.7% net profit margin. Year-over-year quarterly sales growth most recently was 28.1%. Analysts expect adjusted earnings to reach $-3.874 per share for the current fiscal year. Ultragenyx Pharmaceutical Inc. does not currently pay a dividend.

As of September 10, 2026, Arrowhead Pharmaceuticals, Inc. had a $11.7 billion market cap, putting it in the 80th percentile of all stocks. Arrowhead Pharmaceuticals, Inc.’s stock is up 26.1% in 2026, down 3.2% in the previous five trading days and up 198.45% in the past year.

Currently, Arrowhead Pharmaceuticals, Inc. does not have a price-earnings ratio. Arrowhead Pharmaceuticals, Inc.’s trailing 12-month revenue is $669.5 million with a -47.8% net profit margin. Year-over-year quarterly sales growth most recently was 170.9%. Analysts expect adjusted earnings to reach $-3.539 per share for the current fiscal year. Arrowhead Pharmaceuticals, Inc. does not currently pay a dividend.

How We Compare Ultragenyx Pharmaceutical Inc., Arrowhead Pharmaceuticals and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Ultragenyx Pharmaceutical Inc., Arrowhead Pharmaceuticals and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Ultragenyx Pharmaceutical Inc., Arrowhead Pharmaceuticals and Inc. Stock Value Grades

Company	Ticker	Value
Ultragenyx Pharmaceutical Inc.	RARE	na
Arrowhead Pharmaceuticals, Inc.	ARWR	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Ultragenyx Pharmaceutical Inc. does not have a meaningful Value Score. Arrowhead Pharmaceuticals, Inc. has a Value Score of 4, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither Ultragenyx Pharmaceutical Inc., Arrowhead Pharmaceuticals or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Ultragenyx Pharmaceutical Inc., Arrowhead Pharmaceuticals or Inc. is the better investment when it comes to value.

Ultragenyx Pharmaceutical Inc., Arrowhead Pharmaceuticals and Inc. Growth Grades

Company	Ticker	Growth
Ultragenyx Pharmaceutical Inc.	RARE	D
Arrowhead Pharmaceuticals, Inc.	ARWR	F

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Ultragenyx Pharmaceutical Inc. has a Growth Score of 29, which is Weak. Arrowhead Pharmaceuticals, Inc. has a Growth Score of 14, which is Very Weak.

The Growth Stock Winner: No Clear Winner

Neither Ultragenyx Pharmaceutical Inc., Arrowhead Pharmaceuticals or Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Ultragenyx Pharmaceutical Inc., Arrowhead Pharmaceuticals or Inc. is the better investment when it comes to sustainable growth.

Ultragenyx Pharmaceutical Inc., Arrowhead Pharmaceuticals and Inc.’s Momentum Grades

Company	Ticker	Momentum
Ultragenyx Pharmaceutical Inc.	RARE	F
Arrowhead Pharmaceuticals, Inc.	ARWR	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Ultragenyx Pharmaceutical Inc. has a Momentum Score of 10, which is Very Weak. Arrowhead Pharmaceuticals, Inc. has a Momentum Score of 96, which is Very Strong.

The Momentum Grade Winner: Arrowhead Pharmaceuticals, Inc.

As you can clearly see from the Momentum Grade breakdown above, Arrowhead Pharmaceuticals, Inc. is considered to have stronger momentum compared to Ultragenyx Pharmaceutical Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Arrowhead Pharmaceuticals, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Ultragenyx Pharmaceutical Inc., Arrowhead Pharmaceuticals and Inc. Grades

In addition to Growth, Value and Momentum, A+ Investor also provides grades for Estimate Revisions and Quality.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Ultragenyx Pharmaceutical Inc., Arrowhead Pharmaceuticals and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Ultragenyx Pharmaceutical Inc., Arrowhead Pharmaceuticals or Inc. Stock?

Overall, Ultragenyx Pharmaceutical Inc. stock has a Value Score of , Growth Score of 29 and Momentum Score of 10.

Arrowhead Pharmaceuticals, Inc. stock has a Value Score of 4, Growth Score of 14 and Momentum Score of 96.

Comparing Ultragenyx Pharmaceutical Inc., Arrowhead Pharmaceuticals and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.